In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on why she believes supply chain collaboration is becoming increasingly critical today.
The latest news for pharma industry insiders.
MedTech company issues a risk statement, noting fungal contamination.
The latest news for pharma industry insiders.
The company’s Mourenx plant in Southwest France aims to become an API network hub, with first supplies expected by next year.
In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, describes why these pharma supply chain stakeholders are vital in understanding meaningful clinical outcomes.
The latest news for pharma industry insiders.
These taxes on goods—with the potential to take effect in weeks or months—will vary by country, but rates could depend on regulations, industry subsidies, and other factors.
In the fourth part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, explains the value of FDA guidance documents for manufacturers, along with the areas of CGT development that would benefit most from standardization.
The latest news for pharma industry insiders.
The facilities are expected to offer pharma shipment support by addressing time and temperature-specific requirements.
In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, dives into specific areas where FDA investment could have the greatest impact in accelerating approval timelines.
The latest news for pharma industry insiders.
Trump raises the import tax to 25% on the former—while restoring the latter to 25%—in a move that could potentially take effect on March 4.
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, discusses some of the other specific regulatory updates that drug developers be closely monitoring in the current landscape.
The agreement is centered around improving cell culture efficiency and CGT quality.
In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, explains the challenges associated with meeting the FDA’s 2025 CGT forecasted approval goal.
The latest news for pharma industry insiders.
A cohort study investigates the magnitude of lost coverage among pediatric patients, following the conclusion of the pandemic public health emergency.
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, shares how the development of technology will help bolster the pharma logistics industry.
A survey study of US employers aims to determine whether they prioritize financial or nonfinancial criteria when selecting health plans.
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, describes what the approach of pharma companies should be amid the latest/pending tariffs imposed on Canada, Mexico, and China, along with their potential impact on the pharma supply chain.
The company cites a decline in sales and excess inventory as the main contributing factors.
In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, shares how the imposed/pending trade tariffs impact pharma manufacturers.
However, the 10% tariff on imports from China went into effect this morning, with the nation imposing several of it own.
A report offers a comprehensive benchmarking and assessment of pharmaceutical manufacturer engagement with specialty pharmacies.
In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, explains what needs to be done in the United States in order to increase manufacturing output.
What implications will these have on the pharma supply chain?
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, describes the highlights of a recent pharma supply chain security and visibility report that his company released.
